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ABSTRACT
Background and aims Proton pump inhibitors (PPIs)
are among the top 10 most widely used drugs in the
world. PPI use has been associated with an increased
risk of enteric infections, most notably Clostridium
difﬁcile. The gut microbiome plays an important role in
enteric infections, by resisting or promoting colonisation
by pathogens. In this study, we investigated the
inﬂuence of PPI use on the gut microbiome.
Methods The gut microbiome composition of 1815
individuals, spanning three cohorts, was assessed by tag
sequencing of the 16S rRNA gene. The difference in
microbiota composition in PPI users versus non-users
was analysed separately in each cohort, followed by a
meta-analysis.
Results 211 of the participants were using PPIs at the
moment of stool sampling. PPI use is associated with a
signiﬁcant decrease in Shannon’s diversity and with
changes in 20% of the bacterial taxa (false discovery
rate <0.05). Multiple oral bacteria were over-represented
in the faecal microbiome of PPI-users, including the
genus Rothia (p=9.8×10−38). In PPI users we observed
a signiﬁcant increase in bacteria: genera Enterococcus,
Streptococcus, Staphylococcus and the potentially
pathogenic species Escherichia coli.
Conclusions The differences between PPI users and
non-users observed in this study are consistently
associated with changes towards a less healthy gut
microbiome. These differences are in line with known
changes that predispose to C. difﬁcile infections and can
potentially explain the increased risk of enteric infections
in PPI users. On a population level, the effects of PPI are
more prominent than the effects of antibiotics or other
commonly used drugs.
BACKGROUND AND AIMS
Proton pump inhibitors (PPIs) are among the top
10 most widely used drugs in the world. In 2013,
7% of the population of the Netherlands used
omeprazole. In the same year, esomeprazole was
the second largest drug in terms of revenue in the
USA.1 2 PPIs are used to treat GORD and to
prevent gastric and duodenal ulcers.3 4 Of the
general population, 25% report having heartburn
at least once a month, explaining the large demand
for PPIs.4 Nevertheless, PPIs are frequently pre-
scribed or taken for long periods without evidence-
based indication.5 6
PPI use has been associated with increased risk of
enteric infections.5 7–9 A meta-analysis of 23
studies, comprising almost 300 000 patients,
showed a 65% increase in the incidence of
Clostridium difﬁcile-associated diarrhoea among
patients who used PPI.9 In healthcare-related set-
tings, PPI use also increases the risk of recurrent
C. difﬁcile infections.5 Another meta-analysis of
11 280 patients, from six studies evaluating
Salmonella, Campylobacter and other enteric infec-
tions, also found an increased risk due to acid sup-
pression, with a greater association with PPI than
with H2-receptor antagonists.
8 Recently, the Dutch
National Institute for Public Health and the
Environment noticed a marked increase in the
occurrence of campylobacteriosis associated with
increased PPI use in the Netherlands.7
The gut microbiome plays an important role in
these enteric infections.10–13 Gut microbiota can
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Signiﬁcance of this study
What is already known on this subject
▸ Proton pump inhibitors (PPI) use is associated
with increased risk of enteric infections, in
particular with a 65% increase in incidence of
Clostridium difﬁcile infection.
▸ PPI is one of the most commonly used drugs.
▸ Changes in the gut microbiome can resist or
promote the colonisation of enteric infections.
What are the new ﬁndings
▸ PPI use is associated with decreased bacterial
richness and profound changes in the gut
microbiome: 20% of the identiﬁed bacteria in
this study showed signiﬁcant deviation.
▸ Oral bacteria and potential pathogenic bacteria
are increased in the gut microbiota of PPI users.
▸ On the population level we see more microbial
alterations in the gut associated with PPI use
than with antibiotics or other drug use.
How might it impact on clinical practice in
the foreseeable future?
▸ Given the widespread use of PPI, the morbidity
and mortality associated with enteric infections,
and the increasing number of studies
investigating the microbiome, healthcare
practitioners and researchers should take into
consideration the inﬂuence of PPI on the gut
microbiome.
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resist or promote the microbial colonisation of the gut by C. dif-
ﬁcile and other enteric infections through several mechanisms
that either directly inhibit bacterial growth or enhance the
immune system.10 11 Moreover, substituting the gut microbiota
of patients with C. difﬁcile-associated diarrhoea with a healthy
microbiome through faecal transplantation has been proven to
Table 1 Characteristics of the three independent cohorts in this study
Cohort 1: LifeLines-DEEP
(general population)
Cohort 2: patients with IBD
UMCG














Average (SD)* Average (SD)* Average (SD)* Average (SD)* Average (SD)* Average (SD)*
Age 51.94 (13.59) 44.79 (13.58) 50.87 (14.49) 42.45 (14.57) 51.94 (14.27) 44.57 (18.24)
BMI 27.73 (5.10) 25.05 (4.03) 26.14 (5.53) 25.58 (4.72) 26.24 (4.10) 24.16 (4.11)
Gender (% male) 36.36 42.05 61.67 39.17 30.77 33.56
Reads per sample 48879 (43 001) 55 884 (40057) 51 081 (43 990) 52 970 (37787) 43 807 (28604) 65842 (119296)
Antibiotics (%) 2.02 1.02 31.67 16.67 0.00 1.73
IBD (%) 0.00 0.00 100.00 100.00 0.00 0.00
IBS (%) 34.34 25.77 0.00 0.00 90.38 49.48
Diarrhoea (%) (IBS-D and functional diarrhoea together) 7.07 4.47 – – 28.4 17.3
Average bowel movements per day 1.36 (0.53) 1.38 (0.61) – – 1.60 (0.81) 1.92 (1.11)
Anti-TNF-a (%) – – 38.33 28.75 – –
Mesalazine (%) –- –- 26.67 39.58 – –
Methotrexate (%) – – 16.67 5.42 – –
Steroids (%) – – 30.00 20.42 – –
Thiopurines (%) –- – 21.67 37.08 – –
*Unless otherwise stated
IBD, Inflammatory Bowel Disease; IBS, Irritable Bowel Syndrome; SD, standard deviation, BMI, body mass index.
MUMC, Maastricht University Medical Center; PPI, proton pump inhibitor, TNF-a, tumour necrosis factor; UMCG, University Medical Center Groningen.
Figure 1 PPI-associated statistically
signiﬁcant differences in the gut
microbiome. Meta-analysis of three
independent cohorts comprising 1815
faecal samples, showing a cladogram
(circular hierarchical tree) of 92
signiﬁcantly increased or decreased
bacterial taxa in the gut microbiome of
PPI users compared with non-users
(FDR<0.05). Each dot represents a
bacterial taxon. The two innermost
dots represent the highest level of
taxonomy in our data: the kingdoms
Archea and Bacteria (prokaryotes),
followed outwards by the lower levels:
phylum, class, order, family, genus and
species. Red dots represent
signiﬁcantly increased taxa. Blue dots
represent signiﬁcantly decreased taxa.
FDR, false discovery rate; PPI, proton
pump inhibitor.
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cure C. difﬁcile infection.14 The increased incidence of enteric
infections in PPI users and the importance of the gut micro-
biome composition in the development of these infections led




We studied the effect of PPI use on the gut microbial compos-
ition in three independent cohorts from the Netherlands. These
cohorts together comprise 1815 adult individuals, including
healthy subjects and patients with GI diseases. Cohort 1 consists
of 1174 individuals who participate in the general population
study LifeLines-DEEP in the northern provinces of the
Netherlands.15 Cohort 2 consists of 300 patients with IBD from
the department of Gastroenterology and Hepatology University
Medical Center Groningen (UMCG), the Netherlands. Cohort
3 consists of 189 patients with IBS and 152 matched controls
from Maastricht University Medical Center (MUMC), the
Netherlands.
Medication use
Current medication use at the time of stool collection of Cohort
1 participants was extracted from a standardised question-
naire.16 Two medical doctors reviewed all the medication for
1174 participants. PPI use was scored if participants used ome-
prazole, esomeprazole, pantoprazole, lansoprazole, dexlansopra-
zole or rabeprazole. To exclude other possible drug effects on
the gut microbiome, medication use was scored in eight categor-
ies, allowing for later correction of parameters or exclusion of
Figure 2 Signiﬁcantly altered
families in PPI users consistent in three
cohorts. Meta-analysis of three
independent cohorts comprising 1815
faecal samples. The heatmap shows
19 families signiﬁcantly increased or
decreased associated with PPI use in
the gut microbiome for each cohort
and for the meta-analysis
(meta-analysis FDR<0.05). FDR, false
discovery rate; PPI, proton pump
inhibitor.
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certain participants. These categories were medication that: (1)
changes bowel movement or stool frequency, (2) lowers trigly-
ceride levels, (3) lowers cholesterol levels, (4) anti-diabetic medi-
cation (oral and insulin), (5) systemic anti-inﬂammatory
medication (excluding NSAIDs), (6) topical anti-inﬂammatory
medication, (7) systemic antibiotics, including antifungal and
antimalarial medication, and (8) antidepressants including
serotonin-speciﬁc reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), mirtazapine, and
tricyclic antidepressants (TCAs). The deﬁnitions of these cat-
egories are described in the online supplementary appendix.
Analysis of drugs used in Cohort 2 was based on the
IBD-speciﬁc electronic patient record in the UMCG. Current
PPI use, as well as current IBD medication (mesalazines, thio-
purines, methotrexate, steroids, tumour necrosis factor (TNF)-α
inhibitors and other biologicals) were scored at the time of sam-
pling by the gastroenterologist treating the patient with IBD.
Current PPI consumption in the IBS case-control Cohort 3 was
based on self-reported questionnaires. Pseudonymised data for
all three cohorts was provided to the researchers.
Gut complaints and other clinical characteristics
Information on age, gender and body mass index (BMI) was
available for all three cohorts. In Cohort 1, gut complaints were
investigated using an extensive questionnaire that included defe-
cation frequency and the Bristol Stool Scale. Possible IBS and
functional diarrhoea or constipation were determined using self-
reported ROME III criteria. The patients with IBD in Cohort 2
were diagnosed based on accepted radiological, endoscopic and
histopathological evaluation. All the IBD cases included in our
study fulﬁlled the clinical criteria for IBD. IBS in Cohort 3 was
diagnosed by a gastroenterologist according to the ROME III
criteria.
Stool and oral cavity mucus sample collection
A total of 1815 stool samples and 116 oral cavity mucus samples
were collected. Cohorts 1 and 2 used identical protocols to
collect the stool samples. Participants of cohort 1 and 2 were
asked to collect one stool sample at home. Stool samples were
frozen within 15 min after stool production in the participants’
home freezer and remained frozen until DNA isolation. A
research nurse visited all participants to collect the stool samples
shortly after production and they were transported and stored at
–80°C. Participants of cohort 3 were asked to bring a stool
sample to the research facility within 24 h after stool production.
These samples were immediately frozen upon arrival at −80°C.
Oral cavity mucus samples were collected from 116 add-
itional healthy volunteers using buccal swabs.
DNA isolation and analysis of microbiota composition
Microbial DNA from stool samples was isolated with the
Qiagen AllPrep DNA/RNA Mini Kit (cat. # 80204). DNA isola-
tion from oral cavity swabs was performed using the UltraClean
microbial DNA isolation kit (cat.# 12224) from MoBio
Laboratories (Carlsbad, California, USA). To determine the bac-
terial composition of the stool and oral cavity mucus samples,
sequencing of the variable region V4 of the 16S rRNA gene was
performed using Illumina MiSeq. DNA isolation is described in
the Methods section of the online supplementary appendix.
Figure 3 Principal coordinate analysis of 1815 gut microbiome samples and 116 oral microbiome samples. The gut microbiome of PPI users
is signiﬁcantly different from non-PPI users in the ﬁrst coordinate (PCoA1: p=1.39×10−20, Wilcoxon test). For Principal Coordinate 1 there is
a signiﬁcant shift of the gut microbiome of PPI users towards the oral microbiome. PCoA, principal coordinate analysis; PPI, proton pump
inhibitor.
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Taxonomy determination
Bacterial taxonomy was determined by clustering the sequence
reads with UCLUST (V.1.2.22q) with a distance threshold of
97%, using Greengenes (V.13.8) as the taxonomy reference data-
base. Sequencing and the determination of taxonomy are
described in the Methods section of the online supplementary
appendix.
Statistical analysis
In each cohort, differentially abundant taxa in the gut micro-
biome between PPI users and non-PPI users were analysed using
the multivariate statistical framework MaAsLin.17 MaAsLin per-
forms boosted, additive, general linear models between meta-
data and microbial abundance data. After running the
association studies in the individual cohorts, we performed a
meta-analysis of the three cohorts, using the weighted Z-score
method. The Cochran’s Q test was used to check for
heterogeneity. The signiﬁcance cut-off for the Cochran’s Q test
was determined by Bonferroni correction for the 92 signiﬁcant
results: p<5.43×10−4. Differences in richness (the number of
species within a sample), principal coordinate analyses (PCoA)
and Shannon diversity analysis were determined using the
QIIME microbiome analysis software.18 The Wilcoxon test and
Spearman’s correlations were used to identify differences in
Shannon’s diversity and relations between the PCoA scores of
PPI users and non-PPI users, while the χ2 test, Fisher’s exact
test, Spearman’s correlation and Wilcoxon-Mann-Whitney test
(WMW test) were used to determine differences in age, gender,
BMI, antibiotics use, and gut complaints between PPI users and
non-users. In all the microbiome analyses, multiple test correc-
tions were based on the false discovery rate (FDR). An FDR
value of 0.05 was used as a statistically signiﬁcant cut-off.
In addition to the PPI effect, we also tested the inﬂuence of
other commonly used drugs in Cohort 1. Using MaAsLin with
similar settings to those described above, we tested the microbial
Table 2 Taxa and microbiome aspects associated with PPI use and increased risk of C. difficile infection
Taxa or microbiome aspect
Direction in PPI users that increases
the risk of C. difficile infection References of role on risk of C. difficile infection
α diversity Reduced Buffie et al13 Nature. 2015
Chang et al27 Journal of Infectious Diseases. 2008






Decreased Reeves et al26 Gut Microbes. 2011
Antharam et al28 Journal of Clinical Microbiology. 2013.
Buffie et al.13 Nature 2015 (Extended Figure 3d and 3e)
Schubert et al31 Mbio. 2014.







Decreased Buffie et al10 Nature Reviews Immunology. 2013
Rea et al29 Journal of Clinical Microbiology. 2011







Increased Antharam et al28 Journal of Clinical Microbiology. 2013
Schubert et al31 Mbio. 2014
Rea et al29 Journal of Clinical Microbiology. 2011 (Figure 4)
Buffie et al13 Nature. 2015 (Extended Figure 3d and 3e)











Increased Reeves et al26 Gut Microbes. 2011
Antharam et al28 Journal of Clinical Microbiology. 2013
Rea et al 29 Journal of Clinical Microbiology. 2012
Buffie et al10 Nature Reviews Immunology. 2013















Increased Antharam et al28 Journal of Clinical Microbiology. 2013
Reeves et al26 Gut Microbes. 2011
Schubert et al31 Mbio. 2014
Peterfreund et al32 PLOS ONE. 2012
PPI, proton pump inhibitor.
k__, kingdom; p__, phylum; c__, class; o__, order; f__, family; g__, genus; s__, species
associations are in bold
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changes associated with the use of other drugs, with and
without correction for PPI, and the changes when including
these common drugs as a correcting factor in the PPI versus
non-PPI analysis.
Signiﬁcant results were graphically represented in cladograms
using GraPhlAn.19 More details on the statistical analysis can be
found in the Methods section (see online supplementary
appendix).
Correction for factors inﬂuencing the gut microbiota
Differentially abundant taxa were corrected for several para-
meters, which were identiﬁed by statistical analysis of cohort
phenotypes or univariate MaAsLin runs and subsequently added
as cofactors to the additive linear model. Analyses in the general
population Cohort 1 were corrected for age, gender, BMI, anti-
biotics use, sequence read depth and ROME III diagnosis
(IBS-Constipation (IBS-C), IBS-Diarrhoea (IBS-D), IBS-Mixed
(IBS-M), IBS-Undetermined (IBS-U), functional bloating, func-
tional constipation, functional diarrhoea or none). The analysis
of patients with IBD in Cohort 2 was corrected for age, gender,
BMI, antibiotics use, sequence read depth, diagnosis (Crohn’s
disease or UC) combined with disease location (colon, ileum or
both) and IBD medication (use of mesalazines, steroids, thiopur-
ines, methotrexate or anti-TNF antibodies). The analysis of the
IBS case-control Cohort 3 was corrected for age, gender, BMI,
sequence read depth and IBS status according to the ROME III
criteria. In the meta-analysis, all microbiome data were cor-
rected for age, gender, BMI, antibiotics use and sequence read
depth.
RESULTS
PPI use is associated with older age and higher BMI
PPI were used by 211 (11.6%) of the 1815 participants: 8.4%
of the general population (Cohort 1), 20.0% of the patients
with IBD (Cohort 2) and 15.2% of the participants of case-
control Cohort 3. Women use PPI more often than men: 9.2%
versus 7.4%, albeit this was not statistically signiﬁcant (p=0.61,
χ2 test). PPI users were generally older: 51.6 (SD 13.4) years of
age versus 44.4 (SD 14.7) years of age (p=2.50×10-11 WMW
test) and have a higher BMI of 26.9 (SD 5.0) versus 24.9 (SD
4.2) for non-users (p=1.89×10−8, WMW test). Antibiotics
were concomitantly used by 2% of the 99 PPI users of Cohort 1
and 33% of the 60 PPI users of Cohort 2. There was no overlap
between PPI users and antibiotics users in Cohort 3. Based on
our data, we included age, gender, BMI and antibiotics as cofac-
tors in the microbiome analyses. Table 1 provides an overview
of the characteristics per cohort and the use of PPI.
Composition of the gut microbiota
The predominant phylum in each cohort was Firmicutes with
abundances of 76.7%, 73.8% and 77.4% in Cohorts 1, 2 and 3,
respectively. Information on the composition of the gut micro-
biome for all three cohorts and on all taxonomic levels is pro-
vided in online supplementary ﬁgures S1, S2 and table S1.
Independent of PPI use, the overall high-level bacterial compos-
ition of the gut was homogeneous in all three cohorts (by
phylum, class and order level, Spearman’s correlations: r>0.94;
p<1.6×10−13).
Reduced diversity of the gut microbiome associated with PPI use
In all three cohorts we identiﬁed a lower species richness and
lower Shannon diversity, although not signiﬁcant (Cohort 1,
p=0.85 ; Cohort 2, p=0.16; Cohort 3, p=0.53), however in
combined analysis of all three data sets we identiﬁed, moderate
but signiﬁcant decrease in gut α diversity of PPI users was
observed in the meta-analysis of all 1815 gut microbiome
samples: Shannon index (p=0.01) and species richness
(p=0.02) (see online supplementary ﬁgures S3 and S4).
Meta-analysis: differences in gut microbiome associated
with PPI use
The meta-analysis across all three cohorts showed statistically
signiﬁcant alterations in 92 of the 460 bacterial taxa abundance
(FDR<0.05). These changes are depicted in a cladogram in
ﬁgure 1 and in a heatmap in ﬁgure 2, and in online supplemen-
tary ﬁgure S5. Details of each taxon, including the individual
direction, coefﬁcient, p value and FDR for each cohort, as well
as the meta-analysis, are provided in online supplementary
tables S2 and S3. Cochran’s Q test was used to check for hetero-
geneity. None of the 92 reported associations were signiﬁcantly
heterogeneous at the Bonferroni corrected p value cut-off
(p<5.43×10−4) (see online supplementary table S2).
The overall difference of the gut microbiome associated with
PPI use was also observed in the PCoA of all the data sets
together (ﬁgure 3 and see online supplementary ﬁgure S6). The
same PCoA with separate colours for each cohort has been
added in online supplementary ﬁgure S7. Notably, we observed
statistically signiﬁcant differences between PPI users and
non-users in two principal coordinates (PCoA1:
p=1.39×10−20, PCoA3: p=0.0004, Wilcoxon test).
Similar changes in three independent cohorts were
associated with PPI use
The order Actinomycetales, families Streptococcoceae,
Micrococcoceae, genus Rothia and species Lactobacillus salivar-
ius were increased in participants using PPI in each cohort.
None of the individual cohorts contained any signiﬁcantly
decreased taxa (FDR<0.05). In the general population
(Cohort 1), 41 of the 829 bacterial taxa were signiﬁcantly
increased, including the class Gammaproteobacteria, the family
Enterococcoceae and the genera Streptococcus, Veillonella and
Enterococcus (FDR<0.05) (see online supplementary table S4).
In patients with IBD (Cohort 2), PPI use was associated with an
increase of 12 of the 667 bacterial taxa, including the family
Lactobacillaceae as well as the genera Streptococcus and
Lactobacillus (FDR<0.05) (see online supplementary table S5).
In IBS case-control Cohort 3, 18 of the 624 taxa were signiﬁ-
cantly increased, including the order Lactobacillales
(FDR<0.05) (see online supplementary table S6).
Oral cavity bacteria are more abundant in the gut
microbiome of PPI users
We hypothesised that the changes in the gut microbiome asso-
ciated with PPI use are caused by reduced acidity of the stomach
and the subsequent survival of more bacteria that are ingested
with food and oral mucus. Indeed, some of the statistically sig-
niﬁcantly increased bacteria in PPI users (eg, Rothia dentocariosa,
Rothia mucilaginosa, the genera Scardovia and Actinomyces and
the family Micrococcaceae) are typically found in the oral micro-
biome.20 By analysing 116 oral microbiome samples from partici-
pants in Cohort 1, we could compare the overall composition of
bacteria in the oral microbiome with the composition of the gut
microbiome. We observed a statistically signiﬁcant shift in
Principal Coordinate 1 in the gut microbiome samples of the PPI
users towards the oral samples, compared with non-PPI users
(p=1.39×10−20, Wilcoxon test) (ﬁgure 3). In online supplemen-
tary ﬁgure S8, the over-representation of oral cavity bacteria in
the guts of PPI users is depicted in a cladogram.
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PPI use is independent of bowel movement frequency and
stool consistency
Some of the signiﬁcantly increased taxa were more abundant in
the small intestine.11 To ensure that the changes observed in
microbiota composition were not due to diarrhoea and/or more
frequent bowel movements, we checked in our general popula-
tion whether clinical symptoms of diarrhoea were more often
present in PPI users. Neither diarrhoeal complaints (IBS-D and
functional diarrhoea, p=0.22, Fisher’s exact test), stool consist-
ency as deﬁned by the Bristol Stool Scale (r=0.027, p=0.36,
Spearman’s correlation) nor the defecation frequency (r=
−0.001, p=0.98, Spearman’s correlation) of the participants in
Cohort 1 were related to PPI use.
PPI, ANTIBIOTICS AND OTHER COMMONLY USED DRUGS
In Cohort 1, 16 taxa were associated with antibiotics and other
commonly used drug categories besides PPI (see online supple-
mentary table S7). After correction for PPI use, only six taxa
remained associated with certain drugs: statins, ﬁbrates and
drugs that change bowel movements. All 92 alterations in bac-
terial taxa associated with PPI use remained statistically signiﬁ-
cant if we correct the microbiome analyses for antibiotics and
other commonly used drugs.
CONCLUSIONS
We show that PPI use is consistently associated with profound
changes in the gut microbiome. In our study, these changes were
more prominent than changes associated with either antibiotics
or other commonly used drugs. While PPIs have proven to be
useful in the prevention and treatment of ulcers and GORD,
they have also been associated with an increased risk of C. difﬁ-
cile, Salmonella spp, Shigella spp, Campylobacter spp, and
other enteric infections.4 5 7–9 The increased risk of acquiring
one of these enteric infections is likely due to changes in the
PPI user’s gut microbiome. Gut microbiota can resist or
promote colonisation of C. difﬁcile and other enteric infections
through mechanisms that either directly inhibit bacterial growth
or enhance the immune system.10–13 In the case of C. difﬁcile,
spores might be able to germinate more easily because of meta-
bolites synthesised by certain gut bacteria.12 13
We hypothesised that PPIs change the gut microbiome
through their direct effect on stomach acid. This acidity forms
one of the main defenses against the bacterial inﬂux that accom-
panies ingesting food and oral mucus. PPIs reduce the acidity of
the stomach, allowing more bacteria to survive this barrier. We
have shown here that species in the oral microbiome are more
abundant in the gut microbiome of PPI users. Moreover, a study
looking into the effect of PPIs on the oesophageal and gastric
microbiome in oesophagitis and Barret’s oesophagus showed
similar bacterial taxa associated with PPI use, including
increased levels of Enterobacteriaceae, Micrococcaceae,
Actinomycetaceae and Erysipelotrichaceae.21 Gastric bypass
surgery compromises the stomach acid barrier and leads to gut
microbiome changes similar to the PPI-associated alterations in
this study, thereby supporting our hypothesis.22
We looked at the role of the gut microbiome in C. difﬁcile
infections, which cause 12.1% of all nosocomial infections and
were responsible for half a million infections and associated
with 29 000 deaths in the USA in 2011.23 24 Virulent strains of
C. difﬁcile can only colonise a susceptible gut, after which
toxins are produced and spores are shed. This leads to a wide
spectrum of symptoms varying from mild diarrhoea to fulmin-
ant relapsing diarrhoea and pseudomembranous colitis.25
Recent human, animal and in vitro studies show an overlap
between the speciﬁc alterations in the gut microbiota associated
with PPI use found in this study and bacterial changes that lead
to increased susceptibility to C. difﬁcile. The reduced α diversity
in PPI-users is associated with increased susceptibility to C. difﬁ-
cile infection.13 27 28 The PPI-associated decreases of the family
Ruminococcoceae and the genus Biﬁdobacterium, as well as the
PPI-associated increases of the class Gammaproteobacteria, the
families Enterobacteriaceae, Enterococcoceae, Lactobacillaceae
and the genera Enterococcus and Veillonella, have been consist-
ently linked to increased susceptibility to C. difﬁcile infection
(table 2).10 13 26–32
The Ruminococcaceae family is signiﬁcantly decreased in
patients with C. difﬁcile and enriched in healthy controls.28 29 31
Moreover, mice that have been treated with a mixture of anti-
biotics that do not become clinically ill after a challenge with C.
difﬁcile have higher levels of Ruminococcaceae.26 Within the
Ruminococcaceae family, the Faecalibacterium genus was signiﬁ-
cantly increased in patients who recovered from C. difﬁcile
illness, whereas it was severely decreased in patients with C. dif-
ﬁcile with active disease.31 Last, a decreased Ruminococcus
torques operational taxonomic unit (OTU) was signiﬁcantly
associated with C. difﬁcile infection in another study, although
their OTU picking was done using a different reference database
and associations were performed using OTU level, making
direct comparisons with our study difﬁcult.13
Species of the Biﬁdobacterium genus: Biﬁdobacterium
longum, Biﬁdobacterium lactis, Biﬁdobacterium pseudocatenula-
tum, Biﬁdobacterium breve, Biﬁdobacterium pseudolongum,
Biﬁdobacterium adolescentis and Biﬁdobacterium animalis lactis
have been shown to inhibit or prevent C. difﬁcile infection.10
The administration of antibiotics that enhance the susceptibility
to C. difﬁcile in an in vitro model of the gut also signiﬁcantly
reduce the genus Biﬁdobacterium.30 Moreover, active C. difﬁcile
diarrhoea is associated with decreased Biﬁdobacteria in elderly
patients.29
The class Gammaproteobacteria and the family
Enterobacteriaceae are signiﬁcantly increased in PPI users.
Gammaproteobacteria are enriched in patients with C. difﬁcile
compared with healthy controls.28 Within the class
Gammaproteobacteria, the family Enterobacteriaceae dominate
the murine gut microbiome after administration of clindamycin.
Those mice that became clinically ill after the administration of
an antibiotic cocktail containing clindamycin and a C. difﬁcile
challenge, had profoundly increased levels of Enterobacteriaceae
in their gut microbiome, while mice that did not become clinic-
ally ill had a gut microbiome that predominantly consisted of
Firmicutes.26 The family Enterobacteriaceae is also increased in
hamsters that were treated with clindamycin and subsequently
infected with C. difﬁcile.32
The Enterococcus genus, which is also more abundant in PPI
users, is signiﬁcantly enriched in C. difﬁcile-infected patients
compared with healthy controls.28 31 An Enterococcus faecalis
OTU and an Enterococcus avium OTU are signiﬁcantly asso-
ciated with increased susceptibility to C. difﬁcile infections in
mice.13 Moreover, an Enterococcus avium OTU is also signiﬁ-
cantly associated with C. difﬁcile in humans.13 The administra-
tion of the antibiotic ceftriaxone led to an increase in the genus
Enterococcus and enhanced the susceptibility to C. difﬁcile in an
in vitro model of the gut.30
The increased abundance of the family Lactobacillaceae in
PPI users was associated with increased risk of C. difﬁcile infec-
tion in several studies. Mice treated with a cocktail of antibiotics
(consisting of kanamycin, gentamycin, colistin, metronidazole
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and vancomycin), cefoperazone or a combination of clindamy-
cin and cefoperazone have higher levels of Lactobacillaceae in
their gut.26 Mice treated with cefoperazone and clindamycin
that developed C. difﬁcile infection after being challenged with
the pathogen also had a higher level of Lactobacillaceae.26
Within the Lactobacillaceae family, the Lactobacillus genus is
signiﬁcantly enriched in patients with C. difﬁcile infection com-
pared with healthy controls.28 Lactobacillus spp in the gut
microbiome are also associated with active C. difﬁcile diarrhoea
in patients.29 In contrast to these studies, the Lactobacillus
species Lactobacillus delbrueckii, Lactobacillus plantarum and a
Lactobacillus reuteri OTU increased colonisation resistance to
C. difﬁcile.10 13 However, in concordance with increased risk, a
Lactobacillus johnsonii OTU enhanced C. difﬁcile infection.13
Last, the Veillonella genus that is increased in PPI users is sig-
niﬁcantly enriched in patients with C. difﬁcile compared with
healthy controls.28
The prevention of healthcare-associated C. difﬁcile infections
is a priority in the USA and reduction targets for 2020 have
been established.5 33 A recent study looking into the effect of
PPI on the risk of developing recurrent C. difﬁcile infections
found that of 191 PPI users admitted to a hospital, only 47.1%
had an evidence-based indication for PPI use.5 Moreover, PPI
use was discontinued in only 0.6% of the cases.5 The US Food
and Drug Administration already recommends limiting PPI use
to a minimum dose and duration.34 Despite these recommenda-
tions, PPIs are still often overprescribed.5 6 The risk of unneces-
sary antibiotics use is already addressed.35 However, limiting the
unnecessary use of PPI should also be considered in preventing
C. difﬁcile and other enteric infections.
The microbiome is being intensively studied in various dis-
eases and conditions including IBD, IBS, obesity, old age, non-
alcoholic steatohepatitis and non-alcoholic fatty liver disease
(NAFLD).36 PPI users are over-represented in these groups as
they more likely to have GI complaints or experience GORD,
either due to their health condition or their associated lifestyle.
Prominent microbiome studies looking into obesity, IBD and
NAFLD include results that researchers have contributed to
the condition under study, but we show they are also asso-
ciated with PPI use.17 37 It could well be that some of the
observed effects should rather have been attributed to the use
of PPI. Future microbiome studies in humans should therefore
always take the effect of PPI on the gut microbiome into
account.
This paper reports the largest study to date investigating the
inﬂuence of PPI on the gut microbiome. The profound altera-
tions seen in the gut microbiome could be linked to the
increased risk of C. difﬁcile and other enteric infections. Given
the widespread use of PPI, the morbidity and mortality asso-
ciated with enteric infections, and the increasing number of
studies investigating the microbiome, healthcare practitioners
and microbiome researchers should be fully aware of the inﬂu-
ence of PPI on the gut microbiome.
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